Abstract
Despite the existence of good clinical practice guidelines, the way in which they are applied to the bioanalytical laboratory remains unclear. Aspects of patient confidentiality, informed consent and subject withdrawal; addressing unblinding associated with sample analysis, including repeat analysis and incurred sample reanalysis; or the differences in responsibilities between the sponsor and contract research organization are not articulated by the US FDA within the bioanalytical setting, and for most bioanalytical laboratories this remains a gap in their standard operating procedures. The aim of this article is to identify and clarify the aspects of the good clinical practices that are applicable to the bioanalytical laboratory when conducting bioanalysis with clinical samples, and to address potential gaps in the bioanalytical laboratory when it comes to clinical sample bioanalysis.
References
- 1. European Medicines Agency. EMA Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/2009) (2012). www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
- 2. International Conference on Harmonisation. ICH Harmonized Guideline – bioanalytical method validation and study sample analysis M10 (2022). https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf
- 3. International Conference on Harmonisation. ICH E6(R2) Integrated Addendum to ICH E6(R1): guideline for good clinical practice E6(R2) (2016). https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf
- 4. US Food and Drug Administration. US FDA 21 CFR Part 312 – investigational new drug application. www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312
- 5. US Food and Drug Administration. US FDA 21 CFR Part 320 – bioavailability and bioequivalence requirements. www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-320
- 6. US Food and Drug Administration. US FDA 21 CFR Part 812 – investigational device exemptions. www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-812
- 7. US Food and Drug Administration. US FDA 21 CFR Part 50 – protection of human subjects. www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50
- 8. US Food and Drug Administration. US FDA 21 CFR Part 54 – financial disclosure by clinical investigators. www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-54
- 9. US Food and Drug Administration. US FDA 21 CFR Part 56 – institutional review boards. www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-56
- 10. US Food and Drug Administration. US FDA 45 CFR Part 46 – protection of human subjects. www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46
- 11. European Medicines Agency EMA reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples (EMA/INS/GCP/532137/2010) (2012). www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-laboratories-perform-analysis-evaluation-clinical-trial-samples_en.pdf
- 12. . Regulatory guidance gaps associated with clinical sample bioanalysis. Bioanalysis 7(6), 625–628 (2015).
- 13. International Conference on Harmonisation. ICH Harmonized Guideline Good Clinical Practice (GCP) E6(R3) (draft version endorsed) (2023). https://database.ich.org/sites/default/files/ICH_E6%28R3%29_DraftGuideline_2023_0519.pdf
- 14. US Food and Drug Administration. US FDA Guidance for sponsors, clinical investigators, and IRBs – data retention when subjects withdraw from FDA-regulated clinical trials (2008). www.fda.gov/regulatory-information/search-fda-guidance-documents/data-retention-when-subjects-withdraw-fda-regulated-clinical-trials
- 15. European Medicines Agency. EMA Guideline for the notification of serious breaches of regulation (EU) No 536/2014 or the clinical trial protocol (EMA/698382/2021) (2023). www.ema.europa.eu/en/documents/scientific-guideline/guideline-notification-serious-breaches-regulation-eu-no-536/2014-clinical-trial-protocol_en.pdf
- 16. Recommendations for the content and management of certificates of analysis for reference standards from the GCC for bioanalysis. Bioanalysis 13(8), 609–618 (2021).
- 17. US Food and Drug Administration. US FDA bioanalytical method validation guidance for industry (2018). www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
- 18. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312–328 (2006).
- 19. Critical Path Institute: Biomarker Assay Collaborative Evidentiary Considerations Writing Group. Points to consider document: scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices (2019). https://c-path.org/wp-content/uploads/2019/06/evidconsid-whitepaper-analyticalsectionv2019.pdf
- 20. . From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin. Exp. Immunol. 184(2), 137–146 (2016).
- 21. . E6(R3): ICH release draft of overhauled GCP guideline for consultation (2023). www.raps.org/News-and-Articles/News-Articles/2023/5/E6(R3)-ICH-releases-draft-of-overhauled-GCP-guidel